Oncological targets are forbidden to go with drugs.
I. Importance of tumour target-to-medicines
Tumour-oriented drugs play an important role in cancer treatment, but during their use it is essential to understand the taboos associated with other drugs. It has been reported that the incidence of adverse effects due to drug interactions currently exceeds 30 per cent. This means that patients may be exposed to serious health risks if they do not pay attention to the taboos.
Target-oriented drugs have more complex mechanisms for their effect, mostly metabolism through specific enzymes, such as the main CYP3A4 enzymes. Some drugs or food can affect the activity of CYP3A4 enzymes, thus disrupting the absorption and metabolism of target-oriented medicines.
In addition, pH-value drugs that increase stomach fluids can affect the efficacy of the target drug. Medicines that raise pHs in the stomach, such as Renediddin and Esomera, can reduce the absorption of target-to-drugs, thus affecting treatment outcomes.
Understanding these taboos is of great importance for oncological patients. It is not only about the effectiveness of treatment, but also about the health and quality of life of patients. It is only by fully recognizing the importance of taboos that patients can avoid unnecessary risks during treatment, improve the effectiveness of treatment and combat cancer.
Factors affecting the efficacy of the target drug
(i) Principles of drug interaction
The interaction of drugs is the interaction of patients who take two or more drugs at the same time or for a certain period of time. This interaction may strengthen or diminish the efficacy of the drug. Most drugs are metabolized by CYP enzymes, and target drugs are no exception. For example, the CYP3A4 enzyme plays an important role in drug metabolism, which is responsible for 60% of the drug metabolism in the body. It is easy to interact when other drugs are metabolized with the same CYP enzymes. If the activity of CYP enzymes is inhibited, although it increases the blood concentration of the target drug, it does not necessarily enhance the efficacy of the drug, but may lead to an increase in the side effects of the target drug; if more CYP enzymes are induced, it means that the enzymes of the “decomposition” of the target drug have become more numerous, the use of the target-oriented drug has decreased over the same period, and the efficacy of the treatment is not only significantly compromised, but may even reduce the survival benefits of the patient.
(ii) Impact of enzyme induction
Some drugs can induce CYP3A4 enzymes, such as sugar cortex hormones, Lifoping, smoky acne, bentoing, Camasypin, barbiteros, St. John’s grass. These drugs cause high levels of CYP3A4 enzymes and result in high target-to-pharmaceutical metabolism. The short duration and low concentration of the drug in the body has led to the metabolism of the target drug before it has had an anti-cancer effect on the tumour, thus significantly reducing its efficacy.
(iii) Effects of enzymes inhibitors
The components of aphids, pomegranates, pomegranates, furans, fragrances and citrus-like acetone compounds are CYP3A4 enzymes inhibitors, which inhibit the activity of CYP3A4 enzymes. This interferes with human absorption of target-oriented drugs, thus affecting their efficacy. Oncological patients should avoid eating these fruits during the course of the drug.
(iv) Stomach upholstery
The effects of pH-value drugs, such as Renididedin and Esamerazine, which raise pH in the stomach, reduce the efficacy of the target drug. Volatility of PH values in the stomach has some effect on the absorption of target-to-drugs. During the time of taking the drug, the patient must avoid, to the extent possible, co-taking the drugs and food so as not to affect the treatment of the target drug.
III. The taboo on targeting drugs and their compatibility with specific drugs
(i) With CYP3A4 enzyme induction
Medicines such as sugar cortex hormonals, Lifoping, isotope, Bentoing, Camassipin, barbitorella and St. John ‘ s grass are CYP3A4 enzyme inductions. During the use of the target drug, the simultaneous use of the drug should be avoided as much as possible. Data indicate that, while some of the target drugs are co-opted with CYP3A4 enzyme inductions, metabolic rates are significantly increased, and the short time and low concentrations of the drug in the body significantly affect the efficacy of the target drug. If there is a real need for these drugs, it is recommended that the two drugs be administered at least two hours apart. This reduces to some extent the adverse effects of drug interactions and ensures that the target drug can perform its proper therapeutic role.
(ii) With CYP3A4 enzyme inhibitors
Fruits such as grapefruit, pomegranates and pomegranates cannot be eaten with target medicine. These fruits contain components such as thorium, furans frafurbeans and citrus, which inhibit CYP3A4 enzymes. For example, when eating Western grapefruit during the course of a target drug, furan beanin in Western grapefruit interferes with the activity of the liver and the intestinal metabolic enzyme (CYP3A4) and affects the metabolic and therapeutic effects of the drug. Therefore, tumour patients should strictly refrain from eating these fruits during the use of the target drug, so as not to affect the efficacy of the treatment.
(iii) Drugs of pH value with gastrogenic fluids
Medicines that raise pHs in the stomach, such as Renediddin and Esomelala, can reduce the target-to-drug efficacy. Volatility of PH values in the stomach has some effect on the absorption of target-to-drugs. The use of these drugs should be avoided during the course of the drug. If unavoidable, it is also recommended that the time spent on the drug be separated from the target drug by two hours. This reduces the interference with the absorption of the target drug by changes in the pH value within the stomach, and ensures that the target drug works best in the body.
Attention to target drugs and other drugs
(i) Targeting and cold medicine
Oncological patients are less immune and prone to colds during the course of the drug. It is possible to take cold medicine at this time, but it is preferable to choose a medium-form drug with less side effects. When the target drug is taken, hepatosolized capsules, barbituroids, sugar-coated hormones, etc., are not taken, otherwise the target drug is less effective. However, there is no conflict between target and cold drugs, and meeting them does not reduce the canceral effects of the target.
If the cold is severe, medical advice that can be used to spread the tea and to spread the pulmonary pulmonary pills, etc., can be used to alleviate the cold. In case of wind fever, medical advice is given for the use of vasectomy capsules, venomic capsules, wood-hu oral fluids, etc., which have the effect of accommodating and cooling the table. These meds are effective in controlling flu and have relatively small side effects that do not increase the liver and kidney burden and minimize the risk of liver and kidney damage.
(ii) Time interval between target and other drugs
In the case of other drugs, care should be taken of the interval during the time of the drug. For example, when patients with lung cancer catch cold during the target treatment, it is generally recommended that two drugs be administered at intervals of 0.5-1 hours or more. If both the target drug and the cold drug are taken, the patient is advised to take the medication with care to detect liver function.
(iii) Target medicine and use of Chinese medicine
During the course of the targeted treatment, patients with lung cancer can achieve better treatment if they are able to cooperate with Chinese medicine, but it cannot be treated primarily with Chinese medicine, which only acts as a supplement. When a patient uses a target drug, it acts as a disincentive to tumour stoves, and at this time does not blindly use a supplement. Some of the pharmacists are anti-tumour-resistant and, after Western medical treatment, the pharmacological treatments, such as surgical treatment, chemotherapy or decomposition, which are more harmful to the body, are complementary. In the target treatment, the patient ‘ s condition needs to be specifically identified and, after the test, the specific medication used, at which point it is better to use Chinese medicine.
In the treatment of lung cancer, it would be preferable not to use the drug at the same time as the target drug in order not to interact with the drug and affect its efficacy. The specific composition of many medium-sized drugs is unclear and risks allergies. The treatment of lung cancer and the use of drugs are recommended in strict compliance with medical instructions and do not use them on their own.
V. Summary and recommendations
The use of taboos is a crucial issue for patients on tumours during the course of the drug. Understanding and complying with these taboos can be effective in avoiding undesirable drug interactions and in ensuring treatment effectiveness and patient safety.
First, the patient should maintain close communication with the doctor. Before taking a target drug, doctors are informed in detail of other drugs they are using, including prescription drugs, non-prescription drugs, health care items, etc. Doctors can develop individualized treatments based on the patient ‘ s specific circumstances and avoid potential drug interactions.
Secondly, patients must strictly abide by medical instructions. Do not reduce the amount of drugs, replace them or stop them. If there is any discomfort or doubt in the course of the medication, a doctor should be consulted in a timely manner.
For those who need to take multiple drugs at the same time, care should be taken of the interval. At the recommendation of the doctor, the order and time of the drug is rationalized to reduce the risk of drug interaction. In addition, the patient should undergo regular review. Indicators such as blood urine routines and liver and kidney function are monitored to detect and address possible adverse effects in a timely manner.
In general, during the course of the use of the target drug, patients on tumours must be fully aware of the importance of the taboos and take active measures to avoid undesirable interactions and ensure the effectiveness and safety of treatment. Only in this way will it be possible to better combat cancer and improve the quality of life.
